An mRNA vaccine cleared Phase 3 on Keytruda, and the read-through lands on Alteogen

Divide July's subcutaneous Keytruda sales by July's conversion rate and you recover the size of the pool being converted: more than $200 million of monthly SC sales at a 10.6% rate implies about $1.89 billion a month on a wholesale-acquisition-cost basis, or roughly $22.6 billion annualised ^[10][11][20]. On that arithmetic each additional point of conversion relocates on the order of $19 million of monthly revenue into the formulation Alteogen's technology underpins ^[22][18].

Pace matters more than level here. Reaching 10.6% in ten months on the market is an average of about 1.06 points a month, and July alone added 1.7 ^[10][15]. Straight-lining July would put conversion at half the franchise in roughly 23 months ^[21]; that is an extrapolation, not a forecast, and the only support Shinhan Securities offers for durability is that the switch is running faster than for earlier SC oncology drugs ^[12].

The indication mix is what makes the vaccine result travel. Shinhan puts non-small cell lung cancer at about 45% of 2025 Keytruda sales and melanoma at about 10% ^[8], so roughly 55% of the franchise sits in the two tumour types where V940 now has a Phase 3 win and a Phase 3 in progress ^[14]. The lung trial, which began in May, is the first V940 study to pair the vaccine with the SC formulation rather than the intravenous one ^[7].

MSD's position is class-level rather than asset-level. Eight of the nine late-stage V940 trials use Keytruda, about 89% of that programme ^[5][16], and MSD also supplies Keytruda as a combination partner to BioNTech, PDS Biotech and Nykode ^[6]. Combination demand therefore tracks the aggregate hit rate of the vaccine field, not Moderna's alone ^[19]. Alteogen sits one layer below that, and its share of it depends on a protocol-design detail: which formulation each new trial names ^[7][17].

Two cautions on the read. The clinical facts belong to Moderna and MSD, which reported the melanoma result on the 19th ^[1]; the conversion-rate upside and the peak-sales revision are Shinhan Securities' interpretation, published on the 24th on a stock the brokerage covers ^[17][18]. And the Phase 3 effect size is not public yet, with detailed data promised at a conference later this year alongside FDA discussions ^[3]. The percentages currently in circulation are five-year Phase 2b follow-up, not the registrational dataset ^[4].

Which leaves a timing mismatch. If an approval comes, it comes first in adjuvant melanoma, roughly a tenth of Keytruda sales ^[8], while the part that moves Alteogen's numbers is parked in a lung trial that started three months ago ^[7]. MSD is already running Keytruda SC with oral agents and supplying it to outside partners' programmes ^[13], so the direction is set. The size is a 2027 question at the earliest.